Korean J Med.
2015 Oct;89(4):418-427. 10.3904/kjm.2015.89.4.418.
Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction
- Affiliations
-
- 1The Heart Research Center of Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. myungho@chollian.net
- 2The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare, Gwangju, Korea.
- 3Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea.
- 4Department of Nursing, Chonnam National University College of Nursing, Gwangju, Korea.
- 5Department of Nursing, Gwangju Christian College of Nursing, Gwangju, Korea.
- KMID: 2268974
- DOI: http://doi.org/10.3904/kjm.2015.89.4.418
Abstract
- BACKGROUND/AIMS
We compared the efficacy and safety of the second-generation everolimus-eluting stent (EES) and the third generation biolimus-eluting stent (BES) in patients with acute myocardial infarction (AMI).
METHODS
We analyzed 629 consecutive patients (mean age 65.1 +/- 11.2 years, 426 males) with AMI undergoing percutaneous coronary intervention from February 2008 to April 2012. They were divided into two groups according to stent type (EES group, n = 426; BES group, n = 203). The primary end-point was 2-year major adverse cardiac events (MACEs), defined as the composite of all-cause death, myocardial infarction, target vessel revascularization, non-target vessel revascularization and target lesion revascularization. The secondary end-point was 2-year target lesion failure (TLF).
RESULTS
There were no significant differences in baseline characteristics, except that the patients with EES had a significantly higher prevalence of diabetes mellitus (34.7 vs. 22.7%, p = 0.002) and were older (67.1 +/- 11.3 vs. 64 +/- 12.9 years, p = 0.039) compared with the patients with BES. After propensity score matching, 2-year clinical outcomes showed no differences in composite MACEs or TLF between the two groups. Multivariate Cox regression analysis showed that stent type was not a predictor of 2-year mortality or MACEs. However, older age (hazard ratio [HR] 1.037, 95% confidence interval [CI] 1.014-1.060, p = 0.001), diabetes mellitus (HR 2.247, 95% CI 1.426-3.539, p = 0.001) and a left ventricular ejection fraction < or = 45% (HR 3.007, 95% CI 1.978-4.573, p = 0.001) were independent predictors for 2-year MACEs in patients undergoing EES or BES.
CONCLUSIONS
Patients with BES had similar clinical 2-year outcomes compared with EES patients with AMI.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Kounis Syndrome Presenting as Very Late Stent Thrombosis in an Everolimus-Eluting Stent Following Wasp Stings
- Drug-Eluting Stent Used to Treat a Case of Recurrent Right Coronary Artery In-Stent Restenoses often Accompanied by Acute Inferior Wall Myocardial Infarction
- Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching
- A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation
- Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model
